newsfilter
← Latest News
ACCESS Newswire·

CureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSK

Phase 2 study initiated at clinical sites in Australia with monovalent and bivalent mRNA COVID-19 vaccine candidatesVaccine candidates developed in collaboration with GSK within COVID-19 vaccine development